More trials, fewer tribulations.
作者信息
Eisenstein Michael
出版信息
Sci Am. 2014 Jul;311(1):S9-11.
PMID:24974700
Abstract
摘要
相似文献
1
More trials, fewer tribulations.
Sci Am. 2014 Jul;311(1):S9-11.
2
Oncology's first Phase 0 trial.
J Natl Cancer Inst. 2009 Jul 15;101(14):978-9. doi: 10.1093/jnci/djp213. Epub 2009 Jul 7.
3
Can single-patient investigational new drug studies hurry slow trains to the fast track?
Drug Discov Today. 2006 Mar;11(5-6):185-6. doi: 10.1016/S1359-6446(05)03707-4.
4
Institutional profile: Developing and evaluating new drugs for cancer treatment: perspectives from the US National Cancer Institute.
Future Med Chem. 2010 Apr;2(4):555-9. doi: 10.4155/fmc.10.11.
5
NCI-MATCH launch highlights new trial design in precision-medicine era.
J Natl Cancer Inst. 2015 Jul 3;107(7). doi: 10.1093/jnci/djv193. Print 2015 Jul.
6
NCI-MATCH trial pushes cancer umbrella trial paradigm.
Nat Rev Drug Discov. 2015 Aug;14(8):513-5. doi: 10.1038/nrd4694.
7
Drug shortages delay cancer clinical trials.
J Natl Cancer Inst. 2012 Jun 20;104(12):891-2. doi: 10.1093/jnci/djs293.
8
Researchers left to guess at outcomes of most cancer clinical trials.
J Natl Cancer Inst. 2009 Jan 21;101(2):72-4. doi: 10.1093/jnci/djn495. Epub 2009 Jan 13.
9
Clinical trials: More trials, fewer tribulations.
Nature. 2014 May 29;509(7502):S55-7. doi: 10.1038/509S55a.
10
Cancer drugs. Smart weapons prove tough to design.
Science. 2002 Oct 18;298(5593):522-5. doi: 10.1126/science.298.5593.522.
Zotero 插件